Armata Pharmaceuticals (FRA:TG1N) Accounts Payable: €1.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TG1N Armata Pharmaceuticals Inc FRA:TG1N
33 GF Score
Price €3.70
! 5 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals Accounts Payable?

Armata Pharmaceuticals FRA:TG1N +1.65% 33 Accounts Payable is €1.04 Mil as of Jun. 2026. GuruFocus rates FRA:TG1N with a GF Score™ of 33/100. The stock has 5 warning signs investors should review.

Armata Pharmaceuticals's Accounts Payable for the quarter that ended in Jun. 2026 was €1.04 Mil.

Armata Pharmaceuticals's quarterly Accounts Payable declined from Dec. 2025 (€0.79 Mil) to Mar. 2026 (€0.57 Mil) but then increased from Mar. 2026 (€0.57 Mil) to Jun. 2026 (€1.04 Mil).

Armata Pharmaceuticals's annual Accounts Payable declined from Dec. 2023 (€1.45 Mil) to Dec. 2024 (€0.73 Mil) but then increased from Dec. 2024 (€0.73 Mil) to Dec. 2025 (€0.79 Mil).

Armata Pharmaceuticals Accounts Payable Related Terms

Armata Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Armata Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Armata Pharmaceuticals Accounts Payable Chart

Armata Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 1.58 1.45 0.73 0.79

Armata Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 1.09 0.79 0.57 1.04
FRA:TG1N
33GF Score
Armata Pharmaceuticals Inc FRA:TG1N
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Armata Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €1.04 Mil mean?
Armata Pharmaceuticals (FRA:TG1N) has a Accounts Payable of €1.04 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Armata Pharmaceuticals and its competitors.
Is Armata Pharmaceuticals' Accounts Payable too high?
Armata Pharmaceuticals' current Accounts Payable is €1.04 Mil. Overall, Armata Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' Accounts Payable compare to LENZ and OKUR?
Armata Pharmaceuticals' Accounts Payable of €1.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Armata Pharmaceuticals and its competitors. Armata Pharmaceuticals's current Accounts Payable is €1.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (FRA:TG1N) has a current Accounts Payable of €1.04 Mil. The current Accounts Payable is €1.04 Mil. Armata Pharmaceuticals' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Armata Pharmaceuticals (FRA:TG1N), the current Accounts Payable is €1.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Armata Pharmaceuticals Business Description

Other Exchanges ARMP:USATG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
33GF Score

Get the complete analysis for FRA:TG1N

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.70
Price